Carlos Andrés Vergara Sánchez: Insights From the POLY-ACS Trial on Post-ACS Medication Adherence
Carlos Andrés Vergara Sánchez, Chief Cardiovascular Disease Fellow at Mayo Clinic College of Medicine and Science, shared a post on LinkedIn about a recent article by Juan David Coellar et al, adding:
“Simplifying Post‑ACS Care: Insights from the POLY‑ACS Trial.
Medication adherence after ACS remains one of the biggest barriers to preventing recurrent events.
A new pilot study, POLY‑ACS, explored whether simplifying therapy into a single, once‑daily polypill could make a meaningful difference.
Study at a glance:
- 2‑center, open‑label pilot RCT
- 128 ACS patients; median age 58
- 63 percent Hispanic, 63 percent uninsured, 86 percent safety‑net hospitals
- Randomized 30 days post‑discharge
- Intervention: Polypill (ASA + Rosuvastatin 40 mg + clopidogral 75 mg or prasugrel 10 mg)
- Comparator: Usual care
30‑day outcomes assessed:
- LDL‑C
- Platelet reactivity
- Patient‑reported measures (adherence, satisfaction, QoL)
Key findings:
LDL‑C: Polypill led to a significant within‑group reduction; usual care showed no meaningful change (between‑group Non-significant change).
Platelet Reactivity: Maintained inhibition with polypill; worsened with usual care (between‑group Non-significant).
Patient‑Reported Outcomes:
- Higher adherence in the polypill arm
- QoL improved in both groups
- No change in treatment satisfaction
Between group difference were non-significant across all pt reported outcomes.
Most interesting insight:
Among patients with poor baseline adherence, the polypill produced a meaningful LDL‑C drop, with between‑group differences approaching significance.
Those who struggle most with complex regimens may benefit the most from simplification.
Strengths:
- Diverse, socioeconomically vulnerable cohort
- Real‑world antiplatelet regimen included
- Objective biomarker endpoints
Limitations:
- 30‑day follow‑up
- Randomization not at hospital discharge
- Already optimized baseline LDL (57 mg/dL)
Bottom line:
- Post‑ACS mortality is still unacceptably high. We have therapies that work — but adherence remains the Achilles’ heel.
- A polypill won’t solve everything, but it may simplify enough to matter, especially for vulnerable patients.
- Larger, longer‑term trials with clinical outcomes are needed, but this is a great start towards simplifying treatment and reducing pill burden.
See tweetorial by Nathalie Marrero from UM.
Congratulations to the authors on this important work!”
Title: A polypill strategy for lipid lowering and anti-platelet therapy after acute coronary syndrome: A pilot randomized controlled trial
Authors: Juan David Coellar, Neil Keshvani, Anand K. Jain, Muhammad Shariq Usman, Matthew W. Segar, James W. Miller, Myriam Bustillo-Rubio, Dharam J. Kumbhani, Mohanakrishnan Sathyamoorthy, Javed Butler, Subhash Banerjee, Sean Yates, Thomas J. Wang, Ambarish Pandey
Read the Full Article on American Journal of Preventive Cardiology
Read the Editorial.
Stay updated with Hemostasis Today.
-
Jun 24, 2026, 16:32Arlindo Nascimento de Lemos Junior: Thrombus Echogenicity as a Predictor of Post-Thrombotic Syndrome Severity After DVT
-
Jun 24, 2026, 16:09Jimi Olaghere: The Future of Sickle Cell Disease Research Starts With Collaboration
-
Jun 24, 2026, 16:03Von Willebrand Disease as a Common Yet Under-Recognised Bleeding Disorder – EHC
-
Jun 24, 2026, 15:57Maia Meier: Women with Bleeding Disorders Reach the Summit of Mont Blanc
-
Jun 24, 2026, 15:40Annette Bowyer: The Emerging Role of Extravascular Factor VII in Haemostasis
-
Jun 24, 2026, 13:50Tijjani Balas: Why Early Detection of DVT Matters
-
Jun 24, 2026, 13:43Brandon Michael Henry: Interpreting Complement Activation After AAV Gene Therapy
-
Jun 24, 2026, 13:37Heba Youssef: Heparin-Induced Thrombocytopenia – The Prothrombotic Emergency You Cannot Miss
-
Jun 24, 2026, 13:32Jecko Thachil: Understanding the Clinical Spectrum of Vitamin B12